Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Makoto Ueno et al.|The Lancet|2023Cited by 1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Hyun Cheol Chung, Sara Lonardi et al.|Nature|2021Cited by 687